UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 43.

Samaras, P; Pfrommer, S; Seifert, B; Petrausch, U; Mischo, A; Schmidt, A; Schanz, U; Nair, G; Bargetzi, M; Taverna, C; Stupp, R; Stenner-Liewen, F; Renner, C (2015). Efficacy of vinorelbine plus granulocyte colony-stimulation factor for CD34+ hematopoietic progenitor cell mobilization in patients with multiple myeloma. Biology of Blood and Marrow Transplantation, 21(1):74-80.

Ture, M; Barth, J; Angst, F; Aeschlimann, A; Schnyder, U; Zerkiebel, N; Perseus, J; Renner, C; Imesch, P; Fuchs, B; Huber, G F; Walt, H; Martin-Soelch, C; Jenewein, J (2015). Use of inpatient rehabilitation for cancer patients in Switzerland: Who undergoes cancer rehabilitation? Swiss Medical Weekly, 145:w14214.

Passweg, J R; Baldomero, H; Bargetzi, M; Bucher, C; Chalandon, Y; Duchosal, M A; Gratwohl, A; Güngör, T; Hess, U; Leibundgut, K; de Faveri, G N; Ozsahin, H; Pabst, T; Renner, C; Stern, M; Stussi, G; Schanz, U (2013). Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. Swiss Medical Weekly, 143:w13757.

Schuberth, P C; Jakka, G; Jensen, S M; Wadle, A; Gautschi, F; Haley, D; Haile, S; Mischo, A; Held, G; Thiel, M; Tinguely, M; Bifulco, C B; Fox, B A; Renner, C; Petrausch, U (2013). Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Therapy, 20(4):386-395.

Petrausch, U; Schuberth, P C; Hagedorn, C; Soltermann, A; Tomaszek, S; Stahel, R; Weder, W; Renner, C (2012). Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer, 12:615.

Payeli, S K; Kollnberger, S; Marroquin Belaunzaran, O; Thiel, M; McHugh, K; Giles, J; Shaw, J; Kleber, S; Ridley, A; Wong-Baeza, I; Keidel, S; Kuroki, K; Maenaka, K; Wadle, A; Renner, C; Bowness, P (2012). Inhibiting HLA-B27 homodimer-driven immune cell inflammation in spondylarthritis. Arthritis & Rheumatism, 64(10):3139-3149.

Renner, C; Zinzani, P L; Gressin, R; Klingbiel, D; Dietrich, P Y; Hitz, P; Bargetzi, M; Mingrone, W; Martinelli, G; Trojan, A; Bouabdallah, K; Lohri, A; Gyan, E; Biaggi, C; Cogliatti, S; Bertoni, F; Ghielmini, M; Brauchli, P; Ketterer, N (2012). A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica, 97(7):1085-1091.

Engert, A; Haverkamp, H; Kobe, C; Markova, J; Renner, C; Ho, A; Zijlstra, J; Král, Z; Fuchs, M; Hallek, M; Kanz, L; Döhner, H; Dörken, B; Engel, N; Topp, M; Klutmann, S; Amthauer, H; Bockisch, A; Kluge, R; Kratochwil, C; Schober, O; Greil, R; Andreesen, R; Kneba, M; Pfreundschuh, M; Stein, H; Eich, H T; Müller, R P; Dietlein, M; Borchmann, P; Diehl, V (2012). Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet, 379(9828):1791-1799.

Braun, S; Oppermann, H; Mueller, A; Renner, C; Hovhannisyan, A; Baran-Schmidt, R; Gebhardt, R; Hipkiss, A; Thiery, J; Meixensberger, J; Gaunitz, F (2012). Hedgehog signaling in glioblastoma multiforme. Cancer Biology & Therapy, 13(7):487-495.

Mey, U; Hitz, F; Lohri, A; Pederiva, S; Taverna, C; Tzankov, A; Meier, O; Yeow, K; Renner, C (2012). Diagnosis and treatment of diffuse large B-cell lymphoma. Swiss Medical Weekly, 142:w13511.

Motsch, N; Alles, J; Imig, J; Zhu, J; Barth, S; Reineke, T; Tinguely, M; Cogliatti, S; Dueck, A; Meister, G; Renner, C; Grässer, F A (2012). MicroRNA profiling of Epstein-Barr virus-associated NK/T-cell lymphomas by deep sequencing. PLoS ONE, 7(8):e42193.

Luehty, A; Stenner, F; Lohri, C; Muller, C; Samaras, P; Steiner, R; van den Broek, Maries; Mischo, A; Renner, C; Knuth, A; Ruegg, C; Wenger, R H; Zweifel, M (2011). Autologous Stem Cell Transplantation: Leukapheresis Product has Anti-angiogenic Effects In Vivo Correlating with Neutrophil-derived VEGFR1. Anticancer Research, 31(10):3115-3124.

Brokopp, C E; Schoenauer, R; Richards, P; Bauer, S; Lohmann, C; Emmert, M Y; Weber, B; Winnik, S; Aikawa, E; Graves, K; Genoni, M; Vogt, P; Luscher, T F; Renner, C; Hoerstrup, S P; Matter, C M (2011). Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. European Heart Journal, 32(21):2713-2722.

Petrausch, U; Samaras, P; Mischo, A; Stenner, F; Tinguely, M; Schäfer, N; Studer, G; Renner, C (2011). Die Nachsorge beim Hodgkin-Lymphom. Praxis, 100(25):1515-1522.

Craig, V J; Cogliatti, S B; Imig, J; Renner, C; Neuenschwander, S; Rehrauer, H; Schlapbach, R; Dirnhofer, S; Tzankov, A; Müller, A (2011). Myc-mediated repression of microRNA-34a promotes high grade transformation of B-cell lymphoma by dysregulation of FoxP1. Blood, 117(23):6227-6236.

Samaras, P; Blickenstorfer, M; Siciliano, R D; Haile, S R; Buset, E M; Petrausch, U; Mischo, A; Honegger, H; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Stenner-Liewen, F; Renner, C (2011). Pegfilgrastim reduces the length of hospitalization and the time to engraftment in multiple myeloma patients treated with melphalan 200 and auto-SCT compared with filgrastim. Annals of Hematology, 90(1):89-94.

Mischo, A; Bubel, N; Cebon, J S; Samaras, P; Petrausch, U; Stenner-Liewen, F; Schaefer, N G; Kubuschok, B; Renner, C; Wadle, A (2011). Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis. International Journal of Oncology, 39(1):287-294.

Samaras, P; Breitenstein, S; Haile, S R; Stenner-Liewen, F; Heinrich, S; Feilchenfeldt, J; Renner, C; Knuth, A; Pestalozzi, B C; Clavien, P A (2011). Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Annals of Surgical Oncology, 18(7):1924-1931.

Zardavas, D; Meisel, A; Samaras, P; Knuth, A; Renner, C; Pestalozzi, B C; Stenner-Liewen, F (2011). Temsirolimus is highly effective as third-line treatment in chromophobe renal cell cancer. Case Reports in Oncology, 4(1):16-18.

Samaras, P; Blickenstorfer, M; Haile, S R; Siciliano, D; Petrausch, U; Mischo, A; Zweifel, M; Honegger, H; Schanz, U; Stüssi, G; Taverna, C; Bauer, S; Knuth, A; Stenner-Liewen, F; Renner, C (2011). Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience. Swiss Medical Weekly, 141:w13203.

Imig, J; Motsch, N; Zhu, J Y; Barth, S; Okoniewski, M; Reineke, T; Tinguely, M; Faggioni, A; Trivedi, P; Meister, G; Renner, C; Grässer, F A (2011). microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma. Nucleic Acids Research, 39(5):1880-.1893.

Craig, V J; Arnold, I; Gerke, C; Huynh, M Q; Wundisch, T; Neubauer, A; Renner, C; Falkow, S; Mueller, A (2010). Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood, 115(3):581-591.

Burckhart, T; Thiel, M A; Nishikawa, H; Wüest, T; Müller, D; Zippelius, A; Ritter, G; Old, L; Shiku, H; Renner, C (2010). Tumor-specific crosslinking of GITR as costimulation for immunotherapy. Journal of Immunotherapy, 33(9):925-934.

Fischer, E; Kobold, S; Kleber, S; Kubuschok, B; Braziulis, E; Knuth, A; Renner, C; Wadle, A (2010). Cryptic epitopes induce high-titer humoral immune response in patients with cancer. Journal of Immunology, 85(5):3095-3102.

Petrausch, U; Samaras, P; Haile, S R; Veit-Haibach, P; Soyka, J D; Knuth, A; Hany, T F; Mischo, A; Renner, C; Schäefer, N G (2010). Risk adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first line therapy. Annals of Oncology, 21(8):1694-1698.

Petrausch, U; Samaras, P; Veit-Haibach, P; Tschopp, A; Soyka, J D; Knuth, A; Hany, T F; Mischo, A; Renner, C; Schaefer, N G (2010). Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Annals of Oncology, 21(5):1053-1057.

Ospelt, C; Mertens, J C; Jüngel, A; Brentano, F; Maciejewska Rodrigues, H; Huber, L C; Hemmatazad, H; Wüest, T; Knuth, A; Gay, R E; Michel, B A; Gay, S; Renner, C; Bauer, S (2010). Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism, 62(5):1224-1235.

Samaras, P; Heider, H; Haile, S R; Petrausch, U; Schaefer, N G; Siciliano, R D; Meisel, A; Mischo, A; Zweifel, M; Knuth, A; Stenner-Liewen, F; Renner, C (2010). Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP. Annals of Hematology, 89(8):783-787.

Jung, V; Fischer, E; Imig, J; Kleber, S; Nuber, N; Reinshagen, F; Kamradt, J; Grobholz, R; Knuth, A; Renner, C; Wadle, A (2010). Yeast-based identification of prostate tumor antigens provides an effective vaccine platform. Anticancer Research, 30(3):895-902.

Breitenstein, A; Kühne, R; Minder, E I; Marek, A; Goede, J; Schanz, U; Renner, C (2010). Abdominal pain in a patient with acute lymphoblastic leukaemia. Annals of Hematology, 89(2):211-212.

Thiel, M; Wolfs, M J; Bauer, S; Wenning, A S; Burckhart, T; Schwarz, E C; Scott, A M; Renner, C; Hoth, M (2010). Efficiency of T-cell costimulation by CD80 and CD86 cross-linking correlates with calcium entry. Immunology, 129(1):28-40.

Samaras, P; Buset, E M; Siciliano, R D; Haile, S R; Petrausch, U; Mischo, A; Honegger, H; Pestalozzi, B C; Schanz, U; Stüssi, G; Stahel, R A; Knuth, A; Renner, C; Stenner-Liewen, F (2010). Equivalence of pegfilgrastim and filgrastim in lymphoma patients treated with BEAM followed by autologous stem cell transplantation. Oncology, 79(1-2):93-97.

Wadle, A; Mischo, A; Strahl, S; Nishikawa, H; Held, G; Neumann, F; Wullner, B; Fischer, E; Kleber, S; Karbach, J; Jager, E; Shiku, H; Odunsi, K; Shrikant, P A; Knuth, A; Cerundolo, V; Renner, C (2010). NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. FEMS Yeast Research, 27(11):919-931.

Peponi, E; Glanzmann, C; Kunz, G; Renner, C; Tomuschat, K; Studer, G (2010). Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) in nasopharyngeal cancer. Strahlentherapie und Onkologie:135-142.

Renner, C; Zippelius, A; Riethmüller, G; Knuth, A (2010). Tumorimmunologie. In: Hiddemann, W; Bartram, C R. Die Onkologie. Berlin, Deutschland: Springer Medizin Verlag, 325-345.

Bauer, S; Oosterwijk-Wakka, J C; Adrian, N; Oosterwijk, E; Fischer, E; Wüest, T; Stenner, F; Perani, A; Cohen, L S; Knuth, A; Divgi, C; Jäger, D; Scott, A M; Ritter, G; Old, L J; Renner, C (2009). Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. International Journal of Cancer, 125(1):115-123.

Stewart-Jones, G; Wadle, A; Hombach, A; Shenderov, E; Held, G; Fischer, E; Kleber, S; Stenner-Liewen, F; Bauer, S; McMichael, A; Knuth, A; Abken, H; Hombach, A A; Cerundolo, V; Jones, E Y; Renner, C (2009). Rational development of high-affinity T-cell receptor-like antibodies. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 106(14):5784-5788.

Bauer, S; Adrian, N; Siebenborn, U; Fadle, N; Plesko, M; Fischer, E; Wüest, T; Stenner, F; Mertens, J C; Knuth, A; Ritter, G; Old, L J; Renner, C (2009). Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8. Cancer Immunity, 9(2):1-10.

Held, G; Neumann, F; Sturm, C; Kaestner, L; Dauth, N; de Bruijn, D R; Renner, C; Lipp, P; Pfreundschuh, M (2008). Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells. International Journal of Cancer, 123(8):1841-1847.

Stenner, F; Liewen, H; Zweifel, M; Weber, A; Tchinda, J; Bode, B; Samaras, P; Bauer, S; Knuth, A; Renner, C (2008). Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Science, 99(9):1847-1852.

Tinguely, M; Jenni, B; Knights, A; Lopes, B; Korol, D; Rousson, V; Curioni Fontecedro, A; Cogliatti, S B; Bittermann, A G; Schmid, U; Dommann-Scherrer, C; Maurer, R; Renner, C; Probst-Hensch, N M; Moch, H; Knuth, A; Zippelius, A (2008). MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Science, 99(4):720-725.

Curioni-Fontecedro, A; Knights, A J; Tinguely, M; Nuber, N; Schneider, C; Thomson, C W; von Boehmer, I; Bossart, W; Pahlich, S; Gehring, H; Moch, H; Renner, C; Knuth, A; Zippelius, A (2008). MAGE-C1/CT7 is the dominant cancer-testis antigen targeted by humoral immune responses in patients with multiple myeloma. Leukemia, 22(8):1646-1648.

Samaras, P; Dold, S; Braun, J; Kestenholz, P; Breitenstein, S; Imhof, A; Renner, C; Stenner-Liewen, F; Pestalozzi, B C (2008). Infectious port complications are more frequent in younger patients with hematologic malignancies than in solid tumor patients. Oncology, 74(3-4):237-244.

This list was generated on Mon Jul 24 02:43:30 2017 CEST.